CBD Life Sciences Inc (ID) (CBDL)

When is next r/s. Volume slowing. More nonsense from this dilution scam. Tiny little company selling billions of shares over and over. Since last r/s billions issued again.

Shareholder Update
Press Release
OTC Disclosure & News Service | 07/10/2026
Page 1 of 3
https://www.otcmarkets.com/stock/CBDL/news/Shareholder-Update?id=527823

Back to .0001/.0002. Just matter of when another r/s happens.

LOL still tiny revenues. This is a small store. That we can see by revenues being so small. After 6 years of r/s's and dilution. Yet they got rich selling billions of shares before and after each r/s. Same as always sell billions of shares and not much product. Since past r/s billions issued.

CBD Life Sciences Inc. (CBDL) Launches Breakthrough Skincare Line Fusing Apoptogenic Mushrooms and Advanced Peptides
Press Release
OTC Disclosure & News Service | 07/07/2026
Page 1 of 5
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Launches-Breakthrough-Skincare-Line-Fusing-Apoptogenic-Mushrooms-and-Advanced-Peptides?id=527297

CBD Life Sciences Inc. (CBDL) Launches Breakthrough Skincare Line Fusing Adaptogenic Mushrooms and Advanced Peptides

https://www.otcmarkets.com/news-otcapi/news/document/content/id?id=91654

The new clean-beauty collection combines the deeply hydrating, skin-calming power of Tremella and Reishi mushrooms with advanced peptide science to target aging at the cellular level.

SCOTTSDALE, AZ / July 7, 2026 — CBD Life Sciences Inc. (OTC PINK: CBDL), an emerging leader in the natural health and wellness industry and a pioneer in biophilic wellness, today announced the official launch of its highly anticipated skincare collection, the Mushroom Madness Skincare Line. This innovative line represents a major advancement in clean beauty, blending the ancient wisdom of adaptogenic mushrooms with clinically proven, age-defying peptides to repair, plump, and protect the skin barrier.

As consumers increasingly demand high-performance skincare without harsh chemicals, Mushroom Madness has engineered a dual-action formula. The collection utilizes nutrient-dense extracts from Tremella (Snow Mushroom) — which holds up to 500 times its weight in water to outperform traditional hyaluronic acid — and Reishi to calm inflammation and reduce redness. These premium botanicals are paired with a proprietary complex of signal and neurotransmitter peptides. These peptides act as cellular messengers, prompting the skin to build fresh collagen, smooth fine lines, and restore structural firmness from the inside out.

Lisa Nelson, CEO, states: "We wanted to bridge the gap between radical natural healing and clinical laboratory results. Mushrooms are nature's ultimate adaptogens, helping the skin resist environmental stress. By fusing them with peptides, we've created a bio-compatible formula that mimics the skin's natural architecture to deliver rapid, visible lifting and deep, locked-in hydration."

Launch for Mushroom Madness Skincare Line

The initial launch features a curated three-step daily regimen:


Mushroom + Peptide Serum — A concentrated booster targeting deep wrinkles and loss of elasticity.
Tremella Hydro-Cream — An ultra-lightweight, deeply plush moisturizer that locks in moisture for 72 hours.
Reishi Recovery Eye Gel — A cooling formula engineered to rapidly depuff, brighten dark circles, and smooth crow's feet.


True to Mushroom Madness's core values, the entire collection is 100% vegan, cruelty-free, and formulated without synthetic fragrances, parabens, or sulfates. The packaging is consciously crafted from recyclable biophoton glass and FSC-certified paper to minimize environmental impact.

The Mushroom Madness collection will be available starting July 13th exclusively online at [url=https://www.mushroommadess.shop]mushroommadness.shop[/url] and at select luxury wellness retailers nationwide.

Strategic Vision & Responsible Growth

CBDL continues to invest in its operational infrastructure, brand development, and strategic partnerships to support long-term, sustainable growth. As the company strengthens its position in the U.S. market, it is also evaluating additional retail partnerships and future expansion opportunities designed to broaden its market reach and enhance shareholder value.

"Our priority is to deliver high-quality wellness products, including our premium CBD offerings and functional mushroom products featuring Lion's Mane, Reishi, Cordyceps, and Turkey Tail, through trusted and accessible retail channels while continuing to build meaningful relationships with our customers," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As we execute our long-term growth strategy, we remain committed to responsible expansion, continuous product innovation, and creating lasting value for both our consumers and shareholders by providing innovative, science-inspired wellness solutions that support today's evolving health and wellness needs."

Sales and revenue are up 1,000%, yet the stock price isn't moving past $0.0003; what kind of news needs to come out for it to rise further?

CBDL$$$ keeps going, Every journey started with one step at a time.
$$$CBDL will increase values in every step of the way. Let us hope
and pray for CBDL to move forward successfully

LOL and what is the number? Still tiny is why they do not say it.

News - Good morning! $CBDL

We’re happy to announce an increase of over 1,000% on our sales so far this year. This is our biggest YTD thus far!

Some drivers for that are our partners: Walmart ($WMT), DoorDash ($DASH), Groupon ($GRPN), Shopify ($SHOP). https://t.co/pLNe1QG4nr$CBDL— CBD Life Sciences Inc. $CBDL (@CBDL_StockOTC) June 30, 2026

CBD Life Sciences Inc. (CBDL) Reports over 1,000% Revenue Increase from its Online Sales from January to June 2026
Press Release
OTC Disclosure & News Service | 06/30/2026
Page 1 of 5
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Reports-over-1000-Revenue-Increase-from-its-Online-Sales-from-January-to-June-2026?id=526568

Massive growth: CBD Life Sciences $CBDL reports 1,000% online revenue growth Jan–Jun 2026 — annualized over 4,000% as CBD & mushroom supplement demand surges.

Full story: https://www.stockonhighalert.com/post/cbd-life-sciences-inc-cbdl-reports-over-1-000-revenue-increase-from-its-online-sales-from-january


#CBDL #StockNews #CBD #Supplements

CBD Life Sciences Inc. (OTC: CBDL) Reports Over 1,000% Revenue Increase from Online Sales, January–June 2026

CBD Life Sciences Inc. (OTC PINK: CBDL) announced a 1,000%+ increase in revenue from January through June 2026 — an annualized growth rate of over 4,000%. This marks the strongest sustained month-over-month revenue growth in the company's history, driven by its expanding retail, e-commerce, and direct-to-consumer strategy.

CEO Statement

CEO Lisa Nelson said this achievement represents far more than increased sales — it's evidence that CBDL is becoming a trusted wellness brand consumers actively seek out. By focusing on product innovation, expanding consumer access, and building a recognizable brand in the functional wellness market, she said the company has established a scalable foundation for long-term, sustainable growth.

Key Growth Drivers

National Retail & E-Commerce Expansion:

Walmart Marketplace — expanded SKU availability, including the top-selling 3000MG Pain Relief Cream and premium skincare line
DoorDash & Leafly — on-demand local delivery in select markets
Groupon — promotional campaigns to drive first-time customer acquisition
Shopify & Reddit — strengthened DTC sales and community engagement


Product Innovation:

CBD Pain Relief Cream (3000mg/8000mg, 1.7oz/8oz sizes)
CBD Pain-Relief Roll-On Gel
Full-Spectrum CBD Drops (Bubba Kush, Strawnana, Unflavored)
Dubai Mushroom Chocolate (functional mushroom extracts for focus/mood)


Strategic Outlook

The CBD and mushroom supplement markets are forecasted to reach a combined $45 billion by 2028. CBDL says it's evaluating additional retail partnerships and expansion opportunities to broaden market reach and shareholder value, while continuing to invest in operational infrastructure and brand development.

Nelson added that the company's priority is to deliver high-quality wellness products through trusted, accessible retail channels while building meaningful relationships with customers, and that CBDL remains committed to responsible expansion, product innovation, and creating lasting value for consumers and shareholders.

Full press release: https://www.otcmarkets.com/news-otcapi/news/document/content/id?id=91492

This company will be succesful , just need time. hold on your shares to make good money some day soon.

LOL. Another PR meaning nothing. Same as results show for years. Little sales. Notice they never state what they expect to sell in any PR's? Now that we see filing we know why. Not much revenue. Almost again 6 billion o/s after the last r/s. Next up not if when another r/s. Rinse and repeat with this scam. Many times. All the same bs was said before last r/s. How that work out for shareholders.

Looks like news on the way to spoil your short.

Yes news coming https://t.co/3PkChHDqZh— TEN Associates LLC (@TenAssocLLC) June 23, 2026

Okay I agree. Yet what I said about results being tiny is true. All they are is a small business. Yet they have diluted billions 3 times. Before first r/s and after last 2. They sell shares not much product as the filing shows. This is how small they are after 6 years. Wake up. This is about selling shares not the small business results.

NO filings to show results. Only reason they did not file.

What bs? What I wrote is true. Dilution here never ends. Over 5 billion o.s proves it. After last r/s back to here. The only b/s is every PR making it seem like they are selling a lot. That filing says the opposite. It is nothing but a small tiny company.

So, you just spout BS on here ?!?
#AnotherBlock

Thanks. So result even worse. Dilution has them back to over 5 billion shares o/s. This proves what I have said. Tiny results and massive dilution never ends. 5,931,998,727 shares of common stock as of March 31, 2026. Basically the small size of a dispensary that sells billions of shares not much else. .

They file ?!?

For the three Months Ended March 31
2026
Sales $28,236 15,993
Cost of Sales -16,429 -9,091
Gross Profit 11,497

https://www.otcmarkets.com/file/company/financial-report/564899/content

New they are not new. They been diluting and doing r/s since 2020. Where are the filings? If they had good result they file financials. They are bad is why they do not. It is why they never state in any PR what their expected sales are. Why because like last financials filed years ago tiny, losses and massive dilution.

CBDL is stable with .0003. Lots of accumulation. Any new company has great challenges. We wait and see. They have good products that will fly high someday. I am patiently hopeful. Filing will come. The best is yet to come. Cheers.

Same nothing pr. No mention of what revenues they will make. NO filings to show results. Only reason they did not file. Not selling much, losing money and billions in dilution.

Because CBDL trades over-the-counter, it does not have the same strict SEC reporting or listing requirements as major exchanges like the NYSE or NASDAQ. But I believe CBDL management team want a serious growth for their start up business. No one want bankruptcy. Let us hope for the best. Eventually, sooner or later, CBDL must file and report their finance, transparently,

So what. We all know that about CBD. The point is many places sell CBD. This company sells very little of it. Prove me wrong. Show us in what PR they state what they expect to for revenues. None. Then what filings did they file? None. They hide the little revenues, losses and massive on going dilution is why. If the results were good they be filing to show it.

Packerfan9 is so negative against CBDL but thank you for your warning.
Everyone is aware, so please don't repeat your negativity. Life is beautiful and hopeful

(Forbes) CBD has 7 valuable benefits:

CBD is supported by scientific evidence for the following benefits, though in some cases, more research is needed. Consult with your health care provider before using CBD as a treatment option.

1. Pain Relief
According to Jessica Plonchak, a licensed clinical alcohol and drug counselor and clinical director at ChoicePoint Health, CBD modulates ECS receptors (CB1 & CB2), serotonin receptors and TRPV1 receptors, all of which are involved in sending pain signals in the body.

Research suggests that CBD may be effective in alleviating various types of pain, including fibromyalgia, arthritis, cancer-related pain and neuropathic pain. The authors of a 2025 review in Biomolecules concluded that while CBD shows promise as a chronic pain management alternative to traditional pain medications like opioids, more research is needed.[2]

2. Anxiety Reduction
CBD has been used to alleviate anxiety because of its soothing properties, says Hamilton Gaiani, M.D., a double-board-certified psychiatrist and chief medical officer at Firepit Health. “CBD is thought to exert its [anxiety-reducing] effect by binding to the brain’s serotonin receptors,” he explains.

A small 2019 study in The Permanente Journal found that CBD significantly decreased anxiety levels in 79% of participants.[3] And a 2020 review in The Canadian Journal of Psychiatry found that CBD may improve symptoms of anxiety and depression in individuals with mood disorders, although more research is needed.[4]
3. Improved Sleep
CBD may also contribute to better sleep quality, particularly in individuals with insomnia caused by anxiety and trauma, says Dr. Gaiani. It’s believed that CBD’s relaxing effects on the body and mind can help promote a restful night’s sleep. A 2019 study in The Permanente Journal found that CBD improved sleep scores in patients with anxiety and poor sleep quality.[3]

4. Reduces Inflammation
CBD’s anti-inflammatory properties make it a potential treatment for various inflammatory conditions, such as arthritis, inflammatory bowel disease and multiple sclerosis. A 2022 review in Frontiers in Pharmacology concluded that CBD may reduce inflammation by stopping the production of pro-inflammatory cytokines (a group of signaling molecules that amplify inflammation in the body), but more research is needed to understand its exact mechanism of action.[5]

5. Seizure Management
One of the most well-documented benefits of CBD is its effectiveness in managing seizures, particularly in children and adults with epilepsy. Epidiolex, a CBD-based medication, is FDA-approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy, in patients older than 2. According to a 2019 review in Molecules, clinical trials have demonstrated that CBD can significantly reduce the frequency and severity of seizures.[6]

6. Cancer Symptom Relief
For individuals undergoing cancer treatment, CBD may help alleviate chemotherapy-induced nausea and vomiting. A 2020 study in Annals of Oncology found that individuals who received a combination of CBD and THC experienced significant relief from these symptoms, with 25% experiencing no vomiting or nausea compared to 14% who received a placebo.[7] Although the results are promising, the researchers plan to conduct further testing.

7. Helps With Neurological Disorders
CBD has shown promise in treating various neurological disorders, including multiple sclerosis (MS), Parkinson’s disease, Alzheimer’s disease and Huntington’s disease. Research indicates that CBD can help reduce muscle spasms and improve mobility in MS patients. A 2022 review in Frontiers in Pharmacology found that CBD may protect neurons and reduce neuroinflammation, potentially benefiting those with neurodegenerative disorders (Forbes)

The problem is they do not sell much of anything but shares. Billions. Multiple r/s. They do not want people to know that. So they never file financials for years. Last one showed 167,000 in sales. Tiny. They never state what they will sell in any Pr's. They can keep this share selling scam going. By not showing you how bad they are. That keeps people thinking this do well. Yet the massive dilution never stops. Not when all they keep doing is selling billions of new shares.

CBDL someday will fly high.

The company develops, manufactures, and distributes hemp-derived CBD and wellness products, including nicotine-free CBD vapes. CBD stands for Cannabidiol, a natural, non-intoxicating compound found in the cannabis plant. It is widely used in wellness and medical products. To help manage anxiety, pain, and inflammation without causing a "high".

Cannabidiol: a major chemical found in hemp and marijuana. Unlike THC, it does not alter your state of mind. It is commonly extracted into oils, gummies, lotions, and capsules. Medical use? One specific, highly-purified form of CBD is FDA-approved to treat rare seizure disorders in children

More nothing. As always does not say what they expect for revenues. As always no filings to hide how bad sales are and dilution.

$CBDL Bullish Buy average on @barchart see here - https://www.barchart.com/stocks/quotes/cbdl/opinion

$CBDL recently announced the successful execution of a stock purchase agreement with FBC Holding Inc. Under the terms of this agreement, CBD Life Sciences Inc. has purchased 100% of the issued and outstanding stock of Mushroom Madness Inc. and Formrunner Apparel.

This strategic acquisition ensures that both Mushroom Madness Inc. and Formrunner Apparel are now fully wholly owned subsidiaries of CBD Life Sciences Inc. (CBDL). This move represents a significant milestone in our corporate growth strategy, streamlining our operations and consolidating our diverse brand portfolio under the CBD Life Sciences umbrella to maximize shareholder value and operational efficiency

What does that mean in revenues. Again never tell us in PR;s. Never file financials. Why. Do not sell much, losses and billions more in dilution. If results were good they file. Wake up it is scam.

On accumulation $CBDL - news is coming ?

$CBDL ~ Strategic Alignment with a High-Growth Industry

As the CBD market continues to grow at a rapid pace, CBD vapes are becoming a major point of differentiation for innovative companies. Their non-psychoactive properties, along with rising scientific interest and growing consumer awareness, are fueling increased demand across both retail markets and research-focused sectors.

CBDL believes its early entry and focused investment in CBD product development positions the Company to:

Capture first-mover advantage in an emerging CBD category

Expand market share across multiple product verticals

Strengthen brand authority in next-generation cannabinoid innovation

Drive long-term revenue growth and shareholder value

$CBDL Leadership Perspective: Positioning for Long-Term Growth

"CBD vapes are emerging as one of the most promising product opportunities in the CBD supplement industry," said Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc. https://finance.yahoo.com/sectors/healthcare/articles/cbd-life-sciences-inc-cbdl-110000003.html

So how much revenue do they make? They never say that in pr's do they. How much revenue does company do each year. They never file so we do not know. Why do they not file? Simple results still tiny, losses and billions in dilution. If things are so good they file and show it. .

wrong board

The CBD Vapes will be available for purchase now
The FDA Authorizes Fruit-Flavored Vapes for Adults 21 and Up Nationwide.

---

The FDA Authorizes Fruit-Flavored Vapes for Adults 21 and Up Nationwide. CBD Vapes Market size was valued at US$ 5.8 Billion in 2026, and is projected to reach US$ 20.9 Billion by 2033, growing at a CAGR of 20.5% from 2026 to 2033.

SCOTTSDALE, AZ / ACCESS Newswire / May 12, 2026 / CBD Life Sciences Inc. (OTCID:CBDL) CBD Life Sciences Inc. is proud to announce our latest product CBD Flavored Vapes that is Nicotine Free. Our CBD Vape flavors are Menthol, Berry, Tropical and Mint. Vaping CBD allows for quick absorption into the bloodstream, leading to faster effects compared to other consumption methods like edibles or oils. Users often report feeling the calming effects within minutes. The CBD Vapes will be available for purchase in the next two weeks.

Leadership Perspective: Positioning for Long-Term Growth

"CBD vapes are emerging as one of the most promising product opportunities in the CBD supplement industry," said Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc. "As ongoing research continues to highlight their potential, we are taking decisive steps to position CBDL as a leader in this growing market. Our commitment remains focused on expanding a strong CBD product ecosystem while creating lasting value for our shareholders."

Strategic Alignment with a High-Growth Industry

As the CBD market continues to grow at a rapid pace, CBD vapes are becoming a major point of differentiation for innovative companies. Their non-psychoactive properties, along with rising scientific interest and growing consumer awareness, are fueling increased demand across both retail markets and research-focused sectors.

CBDL believes its early entry and focused investment in CBD product development positions the Company to:

Capture first-mover advantage in an emerging CBD category
Expand market share across multiple product verticals
Strengthen brand authority in next-generation cannabinoid innovation
Drive long-term revenue growth and shareholder value

Wen monthly rs?

Told you they they never stop diluting. 4 billion more. If they cannot sell them all. Next up another r/s.

News out…. :-/

The Pr's never state hat they expect to make in revenues. Were are the financials. They never file because they are bad.

CBD Life Sciences Inc. (CBDL) Announces Launch of CBD Flavored Vapes

The FDA Authorizes Fruit-Flavored Vapes for Adults 21 and Up Nationwide. CBD Vapes Market size was valued at US$ 5.8 Billion in 2026, and is projected to reach US$ 20.9 Billion by 2033, growing at a CAGR of 20.5% from 2026 to 2033.

SCOTTSDALE, AZ / ACCESS Newswire / May 12, 2026 / CBD Life Sciences Inc. (OTCID:CBDL) CBD Life Sciences Inc. is proud to announce our latest product CBD Flavored Vapes that is Nicotine Free. Our CBD Vape flavors are Menthol, Berry, Tropical and Mint. Vaping CBD allows for quick absorption into the bloodstream, leading to faster effects compared to other consumption methods like edibles or oils. Users often report feeling the calming effects within minutes. The CBD Vapes will be available for purchase in the next two weeks.

Leadership Perspective: Positioning for Long-Term Growth

"CBD vapes are emerging as one of the most promising product opportunities in the CBD supplement industry," said Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc. "As ongoing research continues to highlight their potential, we are taking decisive steps to position CBDL as a leader in this growing market. Our commitment remains focused on expanding a strong CBD product ecosystem while creating lasting value for our shareholders."

Strategic Alignment with a High-Growth Industry

As the CBD market continues to grow at a rapid pace, CBD vapes are becoming a major point of differentiation for innovative companies. Their non-psychoactive properties, along with rising scientific interest and growing consumer awareness, are fueling increased demand across both retail markets and research-focused sectors.

CBDL believes its early entry and focused investment in CBD product development positions the Company to:

Capture first-mover advantage in an emerging CBD category
Expand market share across multiple product verticals
Strengthen brand authority in next-generation cannabinoid innovation
Drive long-term revenue growth and shareholder value

About CBD Life Sciences Inc. (CBDL)

CBD Life Sciences Inc. (OTC:CBDL) is a high-growth innovator in the cannabinoid and functional wellness sector, focused on developing and commercializing premium CBD and next-generation cannabinoid products. With a rapidly expanding product portfolio and increasing presence across major retail and e-commerce platforms-including Walmart Marketplace-the Company is executing on a strategy designed to capture significant market share in a multi-billion-dollar industry.Driven by innovation, strategic expansion, and a commitment to quality, CBDL is actively positioning itself at the forefront of emerging cannabinoid trends, including CBG and other high-potential compounds. As the Company continues to scale distribution and product offerings, it remains focused on accelerating revenue growth, strengthening brand recognition, and maximizing long-term shareholder value.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Website: https://www.thecbdvault.com

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information

Lisa Nelson
CEO
cbdvaultaz@gmail.com
(480) 209-1720

SOURCE: CBD Life Sciences Inc.


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1166042

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Big deal
No spinoff no dividends no pay back from Gensler and his DEI changes then pocking 99.6
percent of every dollar the SEC won in the Court for the SEC, accountability zero
I do not see one single person or entity being held accountable

Wrong as always. Dilution still never ends here. With no financials that means results not good. Only question same as before. R/s or again at .0001

this stock will move up finally, just need time

Sure I agree. Sell on nay up movement here. It is rare. Eventually like before each r/s. Don't get holding. It wiped out shareholders who thought great buy before each r/s. Same as before rinse and repeat. They make no money so they sell shares not much product.